Intravenous immunoglobulin treatment on anti-GM1 antibodies associated neuropathies inhibits cholera toxin and galectin-1 binding to ganglioside GM1.

Authors:
Address: Shanghai XuHui Centre Hospital, 966 HuaiHai Zhong Road, Shanghai 200031, PR China. pengwei39@hotmail.com
Journal:

Publication:

abstract

Intravenous immunoglobulin (IVIg) therapy is efficacious in some peripheral nervous autoimmune diseases associated with anti-GM1 antibodies. Numerous mechanisms of action have been proposed to account for the immunomodulatory effects of IVIg in immune-mediated diseases. Up to now, the mechanisms of action of IVIg in pathology associated with anti-GM1 antibodies have not been well documented. In the present study, we discovered that IVIg did not inhibit the binding of anti-GM1 antibodies to its antigen and IVIg perfusions did not reduce anti-GM1 antibodies titers. In this observation, we have the result different from the hypothesis of presence of anti-idiotypic antibodies in different IVIg preparations, and show that IVIg inhibits the binding of cholera toxin and galectin-1 to GM1-expressing cells using flow cytometry. Our results suggest that the correct ratio galactosyl/agalactosyl IgG in IVIg interact with macrophages receptors to down-regulate inflammatory function of macrophages and autoimmune diseases in peripheral nerve system.

Related Articles
Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies.
J Neurol Sci. 1996
Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies.
Yuki N, Miyagi F. J Neurol Sci. 1996 Jul; 139(1):160-2.
Normal human plasma contains antibodies that specifically block neuropathy-associated human anti-GM1 IgG-antibodies.
J Neuroimmunol. 2000
Normal human plasma contains antibodies that specifically block neuropathy-associated human anti-GM1 IgG-antibodies.
Lopez PH, Irazoqui FJ, Nores GA. J Neuroimmunol. 2000 Jun 26; 105(2):179-83.
Anti-GM1 antibodies in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg).
J Neuroimmunol. 1994
Anti-GM1 antibodies in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg).
van Schaik IN, Vermeulen M, van Doorn PA, Brand A. J Neuroimmunol. 1994 Oct; 54(1-2):109-15.
Review Mechanisms of action of intravenous immune globulin in immune-mediated diseases.
Clin Exp Immunol. 1996
Review Mechanisms of action of intravenous immune globulin in immune-mediated diseases.
Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD. Clin Exp Immunol. 1996 May; 104 Suppl 1:3-9.
Review Modulation of autoimmune responses by intravenous immunoglobulin (IVIg).
Mult Scler. 1997
Review Modulation of autoimmune responses by intravenous immunoglobulin (IVIg).
Kaveri S, Prasad N, Vassilev T, Hurez V, Pashov A, Lacroix-Desmazes S, Kazatchkine M. Mult Scler. 1997 Apr; 3(2):121-8.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.